key: cord-0869451-430rwv2a
authors: Van Elslande, Jan; Weemaes, Matthias; Godderis, Lode; Van Pottelbergh, Gijs; Bossuyt, Xavier; Vermeersch, Pieter
title: IgG anti-spike antibody levels in healthcare workers with and without prior COVID-19 up to 3 months after BNT162b2 vaccination
date: 2022-01-16
journal: Diagn Microbiol Infect Dis
DOI: 10.1016/j.diagmicrobio.2022.115638
sha: 43c5478b85bec5ff4c0eb9bdf6ee54c845733e51
doc_id: 869451
cord_uid: 430rwv2a

We report IgG anti-spike levels up to three months after vaccination with two doses of BNT162b2 mRNA vaccine in healthcare workers (HCW). The antibody response was significantly stronger in previously infected vaccinated HCW compared to uninfected HCW, and stronger after vaccination compared to (mostly) mild natural infection.

The Pfizer-BioNtech mRNA vaccine BNT162b2 against the severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2) has proven to be effective against Coronavirus Disease 2019 (COVID-19) in large clinical trials as well as in real-life settings [1, 2] . Data from the phase 1 clinical trial of the BNT162b2 vaccine suggest that this vaccine induces higher levels of antibodies compared to natural infection [3] . Recent studies on the short-term antibody response up to 3 weeks after the second dose of the BNT162b2 vaccine showed that previously infected individuals have higher levels of anti-spike antibodies compared to COVID-19 naive individuals [4, 5] .

This study was approved by the local ethics committee at the University Hospitals Leuven (S64152). After obtaining informed consent, we collected serum samples from a cohort of 150 HCW who received two doses of the BN162b2 vaccine with a 21 day interval between both doses at 4 different time points: before the first dose ("baseline", day 0, n=150), 3 weeks after the first dose ("3 weeks", 20-22 days, n=150), 3 weeks after the second dose ("6 weeks", 40-45 days, n=150) and three months after the first dose ("3 months", 89-105 days, n=139). The study cohort included 24 previously infected HCW (Table 1) .

Antibody levels after vaccination were compared with levels in HCW 3 months after positive PCR (median 86 days, range 60-109) (n=112), and hospitalized COVID-19 patients at 6 weeks (median 44 days, range 30-59) (n=64) and 3 months (median 85 days, range 75-105) (n=42) after positive PCR, from previous studies [6, 7] (Table 1) .

Antibodies were measured on Abbott Architect (Abbott, Lake Forest Illinois) with the chemiluminiscence IgG II Quant (anti-S) assays using the manufacturer's cut-offs for positivity 50 AU/mL. As a surrogate for the presence of high neutralizing antibody titer, we determined the proportion of patients with IgG anti-S levels above 4.160 AU/mL ("high titer"). This antibody level has been correlated with a 95% probability for the presence of a neutralizing antibody titer (PRNT ID50) of at least 1:250 ) [4] . See the online data supplement for more information.

IgG anti-S levels were significantly higher in vaccinated HCW with prior COVID-19 compared to COVID-19 naive HCW at each time point (Figure 1 , p<0.001). Previously infected HCW had higher IgG anti-S 3 weeks after the first dose compared to uninfected HCW 3 weeks after the second dose (p<0.001). Antibody levels rose significantly after the first and second dose in naive HCW (p<0.001 each, Figure 1 ). In previously infected HCW, however, there was a significant rise after the first dose, but the rise after the second dose did not reach significance (p=0.14). After 3 months, antibody titers decreased significantly compared to 6 weeks, but remained significantly higher compared to 3 weeks, in both previousy infected and uninfected HCW (p<0.001).

In previously infected HCW median anti-S levels were 24.5 times higher 3 months after vaccination compared to HCW three monts after (mostly mild) natural infection. In previously uninfected HCW, median anti-S levels were 4.6 times higher at this timepoint (p<0.001 for both). In previously infected HCW, we did not observe a correlation between the antibody levels and and the time interval between positive PCR and vaccination (data not shown).

When comparing with hospitalized COVID-19 patients, antibody levels were significantly higher at 6 weeks and 3 months in vaccinated HCW with prior COVID-19 but not in COVID-19 naive vaccinated HCW (Table 1 ). All vaccinated HCW seroconverted for IgG anti-S antibodies at 6 weeks and remained positive up to 3 months after vaccination (Supplementary Table 1 ).

The proportion of individuals with high levels of anti-S antibodies ("high titer", ≥4160 AU/mL), however, varied significantly between groups and changed over time (Table 1) . At 3 weeks, more than 95% of vaccinated HCW with prior COVID-19 already had a high titer compared to less than 1% in COVID-19 naive HCW (p<0.001). At 6 weeks, this proportion increased to 100% and 86%, respectively (p=0.08). For comparison, the percentage of hospitalized COVID-19 patients with a high titer was 72% after 6 weeks (p<0.01 vs. prior COVID-19). At three months, the percentage of individuals with a high titer decreased to 91% and 32% in previously infected and uninfected vaccinated HCW, respectively (p<0.001).

For comparison, only 4% of HCW with a natural infection had a high titer 3 months after natural infection (p<0.001 vs. both). Anti-S titers decreased significantly faster between 6 weeks and 3 months in COVID-19 naive vaccinated HCW (-66%) compared to vaccinated HCW with prior COVID-19 (-47%) and hospitalized COVID-19 patients (n=23, -42%) (p<0.001 for COVID-19 naive HCW vs. both).

We report a stronger antibody response after vaccination in HCW with prior COVID-19 compared to COVID-19 naive HCW. At 3 months, the proportion of participants with a high titer of anti-S suggestive of a high neutralizing antibody titer was significantly higher in previously infected HCW compared to COVID-19 naive HCW, extending the observations of Ebinger et al. who reported a stronger antibody response up to 6 weeks in HCW with prior COVID-19 [4] .

The level of neutralizing antibody titers is linked to the amount of protection, but the exact threshold for protection against (re)infection is not yet known [8] . The fact that only 32% of COVID-19 naive vaccinated HCW had a high titer of anti-S antibodies at three months raises concerns about quick waning of protection against SARS-CoV-2 infection after vaccination, especially in previously uninfected individuals. Our observations suggest that COVID-19 naive individuals might require a third dose of the BNT162b2 vaccine at an earlier time point compared to those with prior COVID-19. These findings are consistent with other recent reports on quick waning of antibody levels after vaccination [9, 10] .

Strenghts of our study are the longitudinal follow-up up to three months with only 7% dropout at three months and the comparison with antibody titers after natural infection.

There are also a number of limitations to our study: the relatively small group of study participants, the use of a surrogate for the presence of neutralizing antibodies and the lack of evaluation of the cellular immune response. 

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Real World Effectiveness of COVID-19 mRNA Vaccines against Hospitalizations and Deaths in the United States

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

Early antibody response in healthcare professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)

Estimated half-life of SARS-CoV-2 anti-spike antibodies more than double the half-life of anti-nucleocapsid antibodies in healthcare workers

Longitudinal follow-up of IgG antinucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers

P. Vermeersch is a senior clinical investigator of the FWO-Vlaanderen.

The research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Dr. Vermeersch reports personal fees from Roche, outside the submitted work.